Clinical Data Analysis Department, National Medical Research Center for Endocrinology, Moscow, Russian Federation.
Laboratory of Molecular Biology, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Hum Mutat. 2022 Dec;43(12):1852-1855. doi: 10.1002/humu.24463. Epub 2022 Sep 12.
RASopathies are disorders caused by germline mutations in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) pathway. These syndromes share features of developmental delay, facial dysmorphisms, and defects in various organs, as well as cancer predisposition. Somatic mutations of the same pathway are one of the primary causes of cancer. It is thought that germline cancer-causing mutations would be embryonic lethal, as a more severe phenotype was shown in Drosophila and zebrafish embryos with cancer MAP2K1 mutations than in those with RASopathy mutations. Here we report the case of a patient with RASopathy caused by a cancer-associated MAP2K1 p.Phe53Leu mutation. The postzygotic mosaic nature of this mutation could explain the patient's survival.
RAS 病是由编码 RAS/丝裂原活化蛋白激酶(MAPK)途径组分的基因种系突变引起的疾病。这些综合征具有发育迟缓、面部畸形和各种器官缺陷以及癌症易感性的特征。相同途径的体细胞突变是癌症的主要原因之一。人们认为种系致癌突变将是胚胎致死的,因为与 RAS 病突变相比,具有癌症 MAP2K1 突变的果蝇和斑马鱼胚胎表现出更严重的表型。在这里,我们报告了一例由与癌症相关的 MAP2K1 p.Phe53Leu 突变引起的 RAS 病患者。这种突变的合子后镶嵌性质可以解释患者的存活。